Description
Considerations on the use of low molecular weight heparins in patients with cancer and chronic kidney disease
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: Considerations on the use of low molecular weight heparins in patients with cancer and chronic kidney disease
€2.42
Related products
-
Article: Highlights in urologic cancer
€2.42 Add to cart -
Article: Highlights in squamous cell carcinoma of the head and neck
€2.42 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€2.42 Add to cart -
Article: Highlights in squamous cell carcinoma of the head and neck
€2.42 Add to cart
Reviews
There are no reviews yet.